Charles Yu is a Principal Scientific Researcher at Genentech, where they lead innovation in iPSC-derived adoptive T cell therapies and advanced in vivo disease models. With a robust background in cell therapy and genetic engineering, they developed a groundbreaking iPSC-derived lymphocyte platform for treating cancer and authored novel sequencing methods like ASIS-Seq. Previously, Yu served as a Senior Research Associate at Lawrence Berkeley Lab, focusing on process optimization for various genomic projects. They are currently pursuing an MBA in Finance at San Francisco State University and a BA in Molecular and Cell Biology, Genetics from UC Berkeley, continuously enhancing their expertise in data-driven decision-making and biotechnology.
This person is not in the org chart
This person is not in any teams
This person is not in any offices